search
Back to results

MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients

Primary Purpose

Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
T Wave Alternans Test
Sponsored by
Medtronic Cardiac Rhythm and Heart Failure
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Myocardial Infarction focused on measuring Myocardial Infarction, Microvolt T Wave Alternans Test, Implantable Cardioverter Defibrillator (ICD), Ventricular Arrhythmia

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients with a history of heart attacks LVEF >0.30 and <= 0.40 as measured by a radionuclide study, angiography or quantitative echocardiography within 3 months prior to enrollment. Exclusion Criteria: Patients with electrocardiographically documented sustained ventricular tachycardia, ventricular fibrillation or prior cardiac arrest (Class I indications) Patients who have undergone an electrophysiologic study with ventricular stimulation or a MTWA test within 1 year prior to enrollment Patients with medical conditions that preclude the testing required by the Investigational Plan or limit study participation Patients unable to complete MTWA testing requirements due to current atrial fibrillation or flutter Patients unable to exercise and for which alternative modalities (pacing or pharmacological stress) used for MTWA testing are not available Patients who have experienced an MI within 1 month prior to enrollment Patients with advanced cerebrovascular disease per physician's assessment Patients classified as NYHA Class IV at time of enrollment Patients who have undergone cardiac revascularization within 3 months prior to enrollment or are scheduled for cardiac revascularization at the time of enrollment Patients with a life expectancy of less than 1 year

Sites / Locations

Outcomes

Primary Outcome Measures

Demonstrate that the life-threatening ventricular tachyarrhythmic event-free survival probability is greater in patients with a baseline MTWA Negative result as compared to patients with a baseline MTWA Positive result.

Secondary Outcome Measures

Compare occurrence of all ventricular events between both groups
Identify predictors of life threatening ventricular arrhythmias
Calculate occurrence of life threatening ventricular arrhythmias based on last MTWA results

Full Information

First Posted
March 20, 2006
Last Updated
February 11, 2008
Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Collaborators
Medtronic
search

1. Study Identification

Unique Protocol Identification Number
NCT00305214
Brief Title
MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients
Official Title
Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients (MASTER II)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2008
Overall Recruitment Status
Completed
Study Start Date
October 2003 (undefined)
Primary Completion Date
February 2007 (Actual)
Study Completion Date
February 2007 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Medtronic Cardiac Rhythm and Heart Failure
Collaborators
Medtronic

4. Oversight

5. Study Description

Brief Summary
The purpose of the study is to determine the usefulness of Microvolt T Wave Alternans (MTWA) testing of patients that have had a heart attack and have decreased pumping ability of the lower chamber of their heart. MTWA testing is a non-invasive test used to detect the likelihood of developing abnormally fast rhythms in the lower chambers of the heart. The objective of the study is to prove that if a patient has a positive MTWA test, they will be more likely to develop abnormally fast and dangerous rhythms in the lower chambers of the heart. The results of the study will help doctors to determine which patients would benefit the most from having an Implantable Cardioverter Defibrillator (ICD) implanted.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction, Arrhythmia, Ventricular, Ischemic Cardiomyopathy
Keywords
Myocardial Infarction, Microvolt T Wave Alternans Test, Implantable Cardioverter Defibrillator (ICD), Ventricular Arrhythmia

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
405 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
T Wave Alternans Test
Primary Outcome Measure Information:
Title
Demonstrate that the life-threatening ventricular tachyarrhythmic event-free survival probability is greater in patients with a baseline MTWA Negative result as compared to patients with a baseline MTWA Positive result.
Secondary Outcome Measure Information:
Title
Compare occurrence of all ventricular events between both groups
Title
Identify predictors of life threatening ventricular arrhythmias
Title
Calculate occurrence of life threatening ventricular arrhythmias based on last MTWA results

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with a history of heart attacks LVEF >0.30 and <= 0.40 as measured by a radionuclide study, angiography or quantitative echocardiography within 3 months prior to enrollment. Exclusion Criteria: Patients with electrocardiographically documented sustained ventricular tachycardia, ventricular fibrillation or prior cardiac arrest (Class I indications) Patients who have undergone an electrophysiologic study with ventricular stimulation or a MTWA test within 1 year prior to enrollment Patients with medical conditions that preclude the testing required by the Investigational Plan or limit study participation Patients unable to complete MTWA testing requirements due to current atrial fibrillation or flutter Patients unable to exercise and for which alternative modalities (pacing or pharmacological stress) used for MTWA testing are not available Patients who have experienced an MI within 1 month prior to enrollment Patients with advanced cerebrovascular disease per physician's assessment Patients classified as NYHA Class IV at time of enrollment Patients who have undergone cardiac revascularization within 3 months prior to enrollment or are scheduled for cardiac revascularization at the time of enrollment Patients with a life expectancy of less than 1 year
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David G. Benditt, MD
Organizational Affiliation
University of Minnesota
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Theodore Chow, MD
Organizational Affiliation
The Lindner Center for Research and Education
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Dean J. Kereiakes, MD, FACC
Organizational Affiliation
The Lindner Center for Research and Education
Official's Role
Study Chair
Facility Information:
City
Mobile
State/Province
Alabama
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Walnut Creek
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Hartford
State/Province
Connecticut
Country
United States
City
Hollywood
State/Province
Florida
Country
United States
City
Naples
State/Province
Florida
Country
United States
City
Safety Harbor
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Joliet
State/Province
Illinois
Country
United States
City
Springfield
State/Province
Illinois
Country
United States
City
Beech Grove
State/Province
Indiana
Country
United States
City
Kansas City
State/Province
Kansas
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Hyannis
State/Province
Massachusetts
Country
United States
City
Grand Rapids
State/Province
Michigan
Country
United States
City
Saginaw
State/Province
Michigan
Country
United States
City
St. Joseph
State/Province
Michigan
Country
United States
City
Minneapolis
State/Province
Minnesota
Country
United States
City
Omaha
State/Province
Nebraska
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
East Islip
State/Province
New York
Country
United States
City
Flushing
State/Province
New York
Country
United States
City
West Islip
State/Province
New York
Country
United States
City
Gastonia
State/Province
North Carolina
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
High Point
State/Province
North Carolina
Country
United States
City
Raleigh
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Cleveland
State/Province
Ohio
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Toledo
State/Province
Ohio
Country
United States
City
Doylestown
State/Province
Pennsylvania
Country
United States
City
Philadelphia
State/Province
Pennsylvania
Country
United States
City
Pittsburgh
State/Province
Pennsylvania
Country
United States
City
Scranton
State/Province
Pennsylvania
Country
United States
City
Spartanburg
State/Province
South Carolina
Country
United States
City
Chattanooga
State/Province
Tennessee
Country
United States
City
Germantown
State/Province
Tennessee
Country
United States
City
Amarillo
State/Province
Texas
Country
United States
City
Corpus Christi
State/Province
Texas
Country
United States
City
Plano
State/Province
Texas
Country
United States
City
Tyler
State/Province
Texas
Country
United States
City
Burlington
State/Province
Vermont
Country
United States
City
Chesapeake
State/Province
Virginia
Country
United States
City
Portsmouth
State/Province
Virginia
Country
United States
City
Appleton
State/Province
Wisconsin
Country
United States

12. IPD Sharing Statement

Learn more about this trial

MASTER II - Microvolt T Wave Alternans Testing for Risk Stratification of Post MI Patients

We'll reach out to this number within 24 hrs